Anemias, particularly those related to iron deficiency, are a common health problem. According to the WHO, about 10% of the population suffers from iron-deficiency anemia caused by various etiological factors, such as nutritional disorders, acute or chronic blood loss, oncological diseases, failure of organs and systems, etc. Solving this problem requires availability of affordable and effective drugs for treatment.

The main tasks in the development of such medicines are to ensure high bioavailability of iron, as well as the ability to achieve an increase in hemoglobin level with a single injection and a low dose. At the same time, the absence of side effects from the gastrointestinal tract and good tolerability of the drug are of great importance. It is important for us to develop both injectable and oral forms, which will allow us to provide assistance to all patients at the outpatient and inpatient stages of treatment. The high efficiency and safety of iron-containing drugs ensure the necessary quality of therapy in accordance with international standards.